Jazz Pharmaceuticals (FRA:J7Z) Inventories, Finished Goods: €103 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
73 GF Score
Price €218.00
GF Value €129.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Inventories, Finished Goods?

Jazz Pharmaceuticals FRA:J7Z -2.37% 73 Inventories, Finished Goods is €103 Mil as of Mar. 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 73/100 and a GF Value™ of €129.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jazz Pharmaceuticals's quarterly finished goods declined from Sep. 2025 (€139 Mil) to Dec. 2025 (€121 Mil) and declined from Dec. 2025 (€121 Mil) to Mar. 2026 (€103 Mil).

Jazz Pharmaceuticals's annual finished goods increased from Dec. 2023 (€128 Mil) to Dec. 2024 (€142 Mil) but then declined from Dec. 2024 (€142 Mil) to Dec. 2025 (€121 Mil).

Jazz Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Inventories, Finished Goods Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 145.43 165.77 128.12 141.85 120.97

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.61 143.02 138.89 120.97 103.37
FRA:J7Z
73GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €103 Mil mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Inventories, Finished Goods of €103 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Inventories, Finished Goods too high?
Jazz Pharmaceuticals' current Inventories, Finished Goods is €103 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Inventories, Finished Goods compare to BBIO and ASND?
Jazz Pharmaceuticals' Inventories, Finished Goods of €103 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Inventories, Finished Goods is €103 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €129.66, compared to a current price of €218.00 — trading 68.1% above its estimated fair value. The current Inventories, Finished Goods is €103 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Inventories, Finished Goods is €103 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €218.00 is trading 68.1% above its estimated GF Value™ of €129.66. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Inventories, Finished Goods: €103 Mil
  • GF Value™: €129.66 vs. price of €218.00 (68.1% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for FRA:J7Z

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€218.00
Price
€129.66
GF Value